Mitomycin¨CC-Induced Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome: Cumulative Toxicity of an Old Drug in a New Era

详细信息    查看全文

• 作者：Roland El-Ghazal¹ ; Nikolai Podoltsev² ; Peter Marks² ; Edward Chu² ; Muhammad Wasif Saif³ ; ^{mws2138@columbia.edu}
• 关键词：Anal squamous cell carcinoma ; Anemia ; Drug toxicity ; Prednisone ; Thrombocytopenia
• 刊名：Clinical Colorectal Cancer
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：10
• 期：2
• 页码：142-145
• 全文大小：232 K

文摘

Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are serious complications of MMC therapy. Herein, we describe a 73-year-old woman with recurrent ASCC treated with MMC who developed chronic microangiopathic hemolytic anemia (MAHA) and thrombocytopenia after receiving a cumulative dose of 50 mg/m². These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids. This report describes an atypically chronic and mild form of secondary TTP/HUS and discusses the possible role of corticosteroids in its management.